Long-term cost-effectiveness of belatacept vs. tacrolimus in kidney transplantation: Trade-off between metabolic benefit and immunological risk. (PubMed, Br J Clin Pharmacol) - Oct 8, 2026 - "Belatacept offers metabolic advantages and modest quality-adjusted survival gains but is not cost-effective vs. tacrolimus owing to substantially higher costs. Whether longer lived or higher metabolic-risk recipients derive acceptable value is a hypothesis requiring dedicated age- and risk-stratified evaluation."
HEOR • Journal • Diabetes • Metabolic Disorders • Solid Organ Transplantation • Transplantation
|
|
Alessio Provenzani; Carmelo Puglia; Salvatore Di Maria
|